Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Disease Prophylaxis

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 2, 2013, Pages 298-304

  Shayani, Sepideh ^a   Palmer, Joycelynne ^b   Stiller, Tracey ^b   Liu, Xueli ^b   Thomas, Sandra H ^c   Khuu, Tam ^a   Parker, Pablo M ^c   Khaled, Samer K ^c   Forman, Stephen J ^c   Nakamura, Ryotaro ^c  

^a Pharmacy Department   (United States)

^b Division of Biostatistics   (United States)

^c Division of Hematology/HCT   (United States)

Author keywords

Calcineurin inhibitors; Schistocytes; Thrombocytopenia

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CASPOFUNGIN; CREATININE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; HEPARIN; ITRACONAZOLE; LACTATE DEHYDROGENASE; MELPHALAN; METHOTREXATE; MICAFUNGIN; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CASE STUDY; CHEMOPROPHYLAXIS; CHILD; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; FEMALE; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DISEASE; LIVING DONOR; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; RISK ASSESSMENT; SCHOOL CHILD; SIBLING; SINUSOIDAL OBSTRUCTIVE SYNDROME; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; THROMBOTIC MICROANGIOPATHIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872609549     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.006     Document Type: Article

References (21)

1. Batts E.D., Lazarus H.M. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress, or are we still waiting?. Bone Marrow Transplant 2007, 40:709-719.
2. Sadler J.E., Poncz M. Antibody-mediated thrombotic disorders: thrombotic thrombocytopenic purpura and heparin induced thrombocytopenia. Williams Hematology 2010, 2163-2183. McGraw-Hill, New York. 8th ed. K. Kaushansky, M. Lichtman, E. Beutler (Eds.).
3. Sadler J.E., Moake J.L., Miyata T., et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology 2004, 407-423. 2004.
4. Ruutu T., Barosi G., Benjamin R.J., et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007, 92:95-100.
5. Chohan R., Vij R., Adkins D., et al. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol 2003, 123:110-113.
6. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
7. Rodriguez R., Nakamura R., Palmer J.M., et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010, 115:1098-1105.
8. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:328-336.
9. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974, 18:295-304.
10. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
11. Kaplan G., Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
12. Statistical Methods in Cancer Research: Volume II, The Design and Analysis of Cohort Studies. IARC Scientific Publication 82 1987, 177-229. IARC, Lyon, France. N.E. Breslow, N.E. Day (Eds.).
13. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
14. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1140-1154.
15. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
16. Rizopoulos D. JM: An R package for the joint modeling of longitudinal and time-to-event data. J Stat Software 2010, 35:1-33.
17. Ho V.T., Cutler C., Carter S., et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:571-575.
18. Cho B.-S., Yahng S.-A., Lee S.-E., et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010, 90:918-926.
19. Fuge R., Bird J.M., Fraser A., et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001, 113:58-64.
20. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008, 112:4425-4431.
21. George J.N., Li X., McMinn J.R., et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion 2004, 44:294-304.